MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Supernus Pharmaceuticals Inc

Fechado

SetorSaúde

32.83 4.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.13

Máximo

32.89

Indicadores-chave

By Trading Economics

Rendimento

-23M

15M

Vendas

-1.5M

174M

P/E

Médio do Setor

24.811

63.778

EPS

0.548

Margem de lucro

8.801

Funcionários

674

EBITDA

-20M

45M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+22.47% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-272M

1.8B

Abertura anterior

28.77

Fecho anterior

32.83

Sentimento de Notícias

By Acuity

16%

84%

28 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Supernus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de abr. de 2024, 18:04 UTC

Grandes Movimentos do Mercado

Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready

Comparação entre Pares

Variação de preço

Supernus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

22.47% parte superior

Previsão para 12 meses

Média 38.8 USD  22.47%

Máximo 44 USD

Mínimo 36 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

2

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.63 / 32.28Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

28 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.